Application of Inflammatory Markers in Induced Sputum in Stable Chronic Obstructive Pulmonary Disease Patients with Positive Bronchodilation Tests

Abstract

Positive bronchodilation (BD) tests can be noticed in some stable chronic obstructive pulmonary disease (COPD) patients. The characteristics of airway inflammation in this entity remain unclear. Our study aimed to identify the characteristics of airway inflammation in stable COPD patients with positive BD tests. The airway inflammation was assessed in 88 patients with stable COPD using the examination of induced sputum in the aftermath of lung function and BD tests. Cellular counts and the levels of molecular markers including eosinophil cationic protein (ECP), myeloperoxidase (MPO), interleukin-5 (IL-5), and IL-8 were assayed by Wright’s stain, Immuno-CAP system, and ELISA, RT-PCR. Among the 88 patients with stable COPD, 20 (22.7%) showed positive BD tests. The values of eosinophils (4.7%±3.4%) and ECP (90.1±41.6 ng/mL) in induced sputum in stable COPD patients with positive BD tests were markedly elevated as compared with those in stable COPD patients with negative BD tests or in healthy controls (all P>0.05), but significantly lower than those in asthmatic patients (all P<0.01). The IL-5 in sputum supernatant was significantly decreased in stable COPD patients with positive BD tests as compared with the patients with asthma (12.5±7.8 vs. 48.2±26.0 ng/mL;.P<0.01). However, healthy controls exhibited similar concentrations of IL-5 in induced sputum with patients with stable COPD, whether with positive or negative BD tests (all P>0.05). Moreover, the values of neutrophils (61.8%±15.1%), MPO (574.0±111.8 ng/mL), and IL-8 (32.6±13.4 ng/mL) in induced sputum in stable COPD patients with positive BD tests were significantly higher than those in asthmatics or normal controls (all P<0.01). However, the values of the above inflammatory markers in induced sputum were similar among stable COPD patients with positive or negative BD tests (all P>0.05). The stable COPD patients with positive BD tests may present not only eosinophilic airway inflammation but also neutrophilic airway inflammation.

References

[1] Global Initiative for Chronic Obstructive Lung Disease COPD.. Global strategy for the diagnosis, management and prevention of COPD; 2016, 2016

[2] HananiaNA, CelliBR, DonohueIF, et al.. Bronchodilator reversibility in COPD. Chest, 2011, 140(4): 1055-1063

[3] ScichiloneN, BattagliaS, La SalaA, et al.. Clinical implications of airway hyperresponsiveness in COPD. Int J Chron Obstruct Pulmon Dis, 2006, 1(1): 49-60

[4] LazarusSC. Role of inflammation and inflammatory mediators in airways disease. Am J Med, 1986, 81(5A): 2-7

[5] EapenMS, MyersS, WaltersEH, et al.. Airway inflammation in chronic obstructive pulmonary disease (COPD): a true paradox. Expert Rev Respir Med, 2017, 11(10): 827-839

[6] Barela-MalczewskaAD, ChazanR. The use of induced sputum examination in respiratory system diseases. Pol Merkur Lekarski, 2011, 30(176): 126-131

[7] MazzeiJA, RocherAE, PalaoroL. Value of sputum analysis in the management of inflammatory airway diseases. Medicma (B Aires), 2012, 72(4): 332-338

[8] PelaiaG, VatrellaA, et al.. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm, 2015, 2015: 879783

[9] Global Initiative for Asthma GINA.. Global strategy for asthma management and prevention; 2016, 2016

[10] MillerMR, HankmsonJ, BrusascoV, et al.. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J, 2005, 26(2): 319-338

[11] HanxiangN, JiongY, YanweiC, et al.. Persistent airway inflammation and bronchial hyperresponsiveness in patients with totally controlled asthma. Int J Clin Pract, 2008, 62(4): 599-605

[12] PavordID, PizzichiniMMM, PizzichiniE, et al.. The use of induced sputum to investigate airway inflammation. Thorax, 1997, 52(6): 498-501

[13] KeatingsVM, JatakanonA, WorsdellYM, et al.. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med, 1997, 155(2): 542-548

[14] AnthonisenNR, WrightEC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis, 1986, 133(5): 814-819

[15] Global Initiative for Asthma GINA.. Global strategy for asthma management and prevention; 2018, 2018

[16] BeehKM, KornmannO, BuhlR, et al.. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest, 2003, 123(4): 1240-1247

[17] KnightDA, HolgateST. The airway epithelium: Structural and functional properties in health and disease. Respirology, 2003, 8(4): 432-446

[18] GanglK, ReiningerR, BernhardD, et al.. Cigarette smoke facilitates allergen penetration across respiratory epithelium. Allergy, 2009, 64(3): 398-405

[19] DyeJA, AdlerKB. Effects of cigarette smoke on epithelial cells of the respiratory tract. Thorax, 1994, 49(8): 825-834

[20] SinghD, KolsumU, BrightlingCE, et al.. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J, 2014, 44(6): 1697-1700

[21] HindsDR, DiSantostefanoRL, LeHV, et al.. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open, 2016, 6(6): 010099

[22] BrightlingCE, McKennaS, HargadonB, et al.. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax, 2005, 60(3): 193-198

[23] LeighR, PizzichiniMM, MorrisMM, et al.. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J, 2006, 27(5): 964-971

[24] KerstjensHA, BrandPL, HughesMD, et al.. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease: Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med, 1992, 327(20): 1413-1419